Navigation Links
With Bone Marrow Transplants Rising, New Therapy Gives Hope to Those Over 55

NEW YORK, Jan. 8, 2014 /PRNewswire/ -- Bone marrow transplants are a $1.3 billion market and the fastest-growing hospital procedure in the U.S. They are the only potential cure for many blood cancers such as acute myeloid leukemia (AML) in older patients. The procedure is technically called hematopoietic stem cell transplantation (HSCT) and can be either a bone marrow transplant (BMT) or transplant of blood stem cells isolated from peripheral blood (PBSC). In either case, it involves transplanting cells capable of restoring normal bone marrow function into a patient.

An increasing number of HSCT patients are over age 55, but many in this group who need it are ruled ineligible. This is because the high-dose chemotherapy traditionally preceding HSCT—standard therapy for younger patients—is often deemed too harsh even for healthy looking older people. Indeed, in certain indications, less than 10 percent of those 55+ survive more than a year after conventional HSCT.

Since more than half of AML patients are over 65 years old, new tactics are needed. For example, what if a patient's existing bone marrow could be "prepared" prior to the transplant in a way that eliminated the need for high-dose chemotherapy? This promising approach is being pursued by an innovative New York City-based biotech company, Actinium Pharmaceuticals, Inc.

Actinium's lead compound, Iomab™-B, has been successfully harnessed as a "myeloconditioning" agent in Phase 1/2 trials involving more than 250 patients including cases of incurable blood cancers such as AML resistant to available therapies. It has demonstrated the ability to prepare such patients for bone marrow transplants when no other treatment was indicated. The targeting part of Iomab™-B is a monoclonal antibody that targets CD45, an antigen widely expressed on white blood cells but not on other tissues.

Very significantly, treatment with Iomab™-B prepares a patient for bone marrow transplant in only 10 days, compared to approximately six weeks required with traditional care—a potentially vital difference in the face of a fast-evolving cancer.

"The only potentially curative treatment option for older AML patients is bone marrow transplant, but the majority of patients over age 55 are ineligible for conventional care due to health reasons and/or severity of their disease," says Kaushik J. Dave, Ph.D., President and CEO of Actinium Pharmaceuticals, Inc. "We believe Iomab™-B offers a positive step toward their continued treatment. Almost all patients are eligible, and preliminary studies indicate their survival rates are significantly higher as a result. It also can help prepare older patients for bone marrow treatment who have survived chemo but whose AML either was not cured or returned."

On the strength of results showing its potential in Phase 1/2 trials, the company is poised to begin a Phase 3 trial during 2014. The primary endpoint will be the rate of durable complete remission among the treated patients. A series of physician-led trials involving Iomab™-B is also ongoing.

For more information, visit, who paid for the writing and dissemination of this release.

Contact:  Laura Radocaj, Dian Griesel Int'l.  212.825.3210

SOURCE Actinium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Enlivex Therapeutics Publishes Positive Results from Phase I/II Clinical Trial for the Treatment of Bone Marrow Transplant Recipients
2. Chimerixs Antiviral CMX001 Abstract Selected for an Oral Presentation at the European Group for Blood and Marrow Transplantations Annual Meeting
3. The Princess Margaret BMT Program Chooses Remedy Informatics Blood and Marrow Transplant & Cell Therapy Solutions to Power their fight Against Cancer
4. Adoption of Prefillable Syringes Rising, Especially In High-cost Drug Applications to Contain Wastage, Notes Frost & Sullivan
5. Scioderm Initiates Phase 2B Study of SD-101, A Novel Topical Therapy, for Patients with Epidermolysis Bullosa
6. Alpha and Omega Gene Therapy Eye Creams Scientific Blend Removes Years of Damage
7. FDA Clears the Provant Therapy System for Use by Patients with Metallic Implants
8. Norgine and Innovacell Enter Into an Exclusive Licensing Agreement for ICEF15 - An Innovative Personalised Cell Therapy to Treat Faecal Incontinence
9. NW Bio Responds To Shareholder Inquiries Following Immune Therapy Sectors Recent Market Decline
10. FDA Issues Complete Response Letter for Canagliflozin/Metformin Fixed-Dose Combination Therapy for Type 2 Diabetes
11. Novartis highlights research on investigational, personalized T cell therapy CTL019 in patients with forms of acute and chronic leukemia
Post Your Comments:
(Date:11/26/2015)... 26, 2015 ... of the  "2016 Future Horizons and ... Drug Monitoring (TDM) Market: Supplier Shares, ... Opportunities"  report to their offering.  ... the addition of the  "2016 Future ...
(Date:11/26/2015)... , Nov. 26, 2015 Research ... addition of the "2016 Future Horizons and ... (TDM) Market: Supplier Shares, Country Segment Forecasts, Competitive ... --> --> ... analysis of the Italian therapeutic drug monitoring market, ...
(Date:11/25/2015)... 25, 2015 ... the "Global Brain Monitoring Devices Market ... --> ) has announced the ... Devices Market 2015-2019" report to their ... ( ) has announced the addition ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... 27, 2015 , ... A team of Swiss doctors has released a report ... has just posted the findings on the website. Click here to read the ... 136 mesothelioma patients who were treated with chemotherapy followed by EPP surgery. Among the ...
(Date:11/27/2015)... ... 2015 , ... Lizzie’s Lice Pickers just announced a special promotion that will ... their purchase of lice treatment product. In addition, customers will receive a complimentary head ... “Finding lice is a sure way to ruin the holidays, so we encourage all ...
(Date:11/27/2015)... ... , ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% of ... than 3.7 billion people under the age of 50 – or 67% of the population ... global estimates of HSV-1 infection . , "The data shocks us highly!" said Michelle ...
(Date:11/27/2015)... ... ... A simply groundbreaking television series, "Voices in America", which is hosted by Hollywood legend, ... that are presently affecting Americans. Dedicated to providing the world with a wide variety ... consumers focus on, one episode at a time. , In the latest installment ...
(Date:11/27/2015)... Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... Commission on Accreditation of Allied Health Education Programs (CAAHEP) awarded accreditation to its Diagnostic ... list of CAAHEP accredited colleges, as only one of twelve colleges and universities in ...
Breaking Medicine News(10 mins):